Growth Factors
CJC-1295 / Ipamorelin
GH Blend
CJC-1295 and Ipamorelin blend
Research context
This preparation combines CJC-1295, a GHRH receptor analogue, with ipamorelin, a selective growth hormone secretagogue receptor (GHS-R1a) agonist. The two act at distinct receptors, and the combination appears in literature examining additive effects on pituitary secretion in cell and animal preparations.
Common assays: Component identity by LC-MS · Purity per component · Pituitary secretion assays
Specification
| Designation | GH Blend |
|---|---|
| Full name | CJC-1295 and Ipamorelin blend |
| Components | CJC-1295 · Ipamorelin |
| Formats | 10 mL Vial · 15 mL Nasal Spray · 15 mL Oral Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
| Current lot | CI1010N1125 → |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Raun K, Hansen BS, Johansen NL, et al.Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology · 1998 Find on PubMed ↗
Common questions
Why are GHRH analogues and GHRPs studied together?
They act at different receptors — the GHRH receptor and GHS-R1a respectively — and published work examines whether combined engagement produces additive secretion effects in pituitary preparations.
What makes ipamorelin described as selective?
Published characterisation reports GHS-R1a agonism with minimal effect on cortisol and prolactin relative to earlier secretagogues in the same class.
Same pathway
Related compounds
CJC-1295
GHRH analog
A tetrasubstituted analogue of growth hormone-releasing hormone (1-29), studied in pituitary secretion research.
Tesamorelin
GHRH analog
A stabilised 44-residue GHRH analogue carrying an N-terminal hexenoyl modification.
IGF-1 LR3
Insulin-like growth factor-1 LR3
An 83-residue IGF-1 analogue engineered for reduced binding-protein affinity.